Biologics Market

Category : Healthcare & Life Sciences Reports | Delivery Format : PDF,PPT | Publisher: Reports and Insights | Pages : 299

To learn more about this report, request a free sample copy

Biologics Market Overview

The report is titled ‘Biologics Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the biologics market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. The biologics market is expected to grow at a significant rate in the near future.

The global biologics market was valued US$ 294.4 Bn at the end of 2020 and expected to reach at a value of US$ 529.3 Bn by 2028 with a significant CAGR of 7.6%.

Biologics Introduction

Biologics, or a biologic drug, is a substance that is made from living creatures or comprise elements of living creatures. Biologic drugs consist of an extensive range of by-products obtained from microorganisms, animals, and humans by the usage of biotechnology. The various kinds of biologic drugs or biologics comprises blood and its components, cells, vaccines, genes, allergens, tissues, and recombinant proteins.

Biologics Market Dynamics

A biologic is created in a life system including animal or plant cells, or microorganisms that are majorly used to impede, diagnose, and to treat, or cure a wide range of illnesses such as chronic kidney disease, cancer, infectious diseases, and autoimmune disorders.

In the present times, the rising incidence of chronic diseases such as autoimmune diseases, diabetes, and cancer among the population owing to the lethargic lifestyle, poor diet, and desk-bound jobs is mainly encouraging the demand of biologics in the global market, thus propelling the growth of the global biologics market.

In addition to that, the constant research activities, across the world, resulting in therapeutic diversification of biologics across varied indicators such as allergic conditions, asthma, dyslipidemia and other non-conventional disease areas, is another major factor that is driving the overall growth of the global biologics industry.

However, due to the inadequacy of reimbursements for biologics as well as heavy cost, there is a shortage of biologics especially in mid to low income economies around the world. Such factors may hold back the growth of the global biologics market over the coming years.

biologics market image

Biologics Market Segmentation

The global biologics market is segmented on the basis of drug class, therapeutic application, distribution channel, and regions. On the basis of the drug class, the biologics market is segmented into Monoclonal Antibody, Vaccine, Recombinant Insulin, Human Growth Hormone, Blood Factor, Fusion Protein, Erythropoietin, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Cell Therapy, Gene Therapy, Oligonucleotides and Others (Peptide, Botulinum Toxin, and Others). Based on therapeutic application, the market is bifurcated into Oncology, Metabolic Disorders, Autoimmune/Immunologic Diseases, Ophthalmic Diseases, Inflammatory Bowel Diseases (IBDs), Respiratory Disorders, Neurological Disorders, Musculoskeletal Disorders (MSDs), Cardiovascular Diseases (CVDs), Infectious Diseases, and Others. On the basis of the distribution channel, the market is categorized into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies.

The research report classifies the global biologics market based on drug class, therapeutic application, distribution channel, and regions.

By Drug Class

Monoclonal Antibody

Vaccine

Recombinant Insulin

Human Growth Hormone

Blood Factor

Fusion Protein

Erythropoietin

Recombinant Enzyme

Interferon

Colony-stimulating Factor

Cell Therapy

Gene Therapy

Oligonucleotides

By Therapeutic Application

Oncology

Metabolic Disorders

Autoimmune/Immunologic Diseases

Ophthalmic Diseases

Inflammatory Bowel Diseases (IBDs)

Respiratory Disorder

Neurological Disorders

Musculoskeletal Disorders (MSDs)

Cardiovascular Diseases (CVDs)

Infectious Diseases

Others

By Distribution Channels

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

Latin America

Africa

Europe

Asia Pacific

Middle East

Biologics Market Key Players

The global biologics market is dominated by Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc., among others.

MMC Overview on Biologics Market Report

The non-identical approach of Reports and Insights stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.

A research report on the biologics market by Reports and Insights is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support the market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

New product designs and launches

Current product compliance

Reimbursement

Concerns for use of biologics

Advantages of biologics

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to make informed decisions.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s products sales, previous growth rates and market expansion plans are considered to generate market share in the global market.


To learn more about this report, request a free sample copy


1.    Global Biologics Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Biologics Market Overview

2.1.    Introduction

2.1.1.    Introduction

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Biologics Market Snapshot

2.4.    Global Biologics Market Size And Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast And Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Biologics Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Porter’s Five Forces Model

2.7.    SWOT Analysis

3.    Biologics Assessment and Analysis

3.1.    Biologics Impact Analysis 

3.2.    Actions to encourage use of Biologics

3.3.    Biologics Promotional Strategy Recommendation

3.4.    Road Map Analysis

3.5.    GAP Analysis

3.6.    Potential Analysis

4.    Covid-19 Impact on Biologics Market

4.1.    Impact Analysis of Covid-19 on the global Biologics market

4.2.    Effect On Value Chain

4.3.    Business Impact W.R.T Revenue 

4.4.    Fluctuation In Production

4.5.    Volatility In Price 

4.6.    Effect On The Overall Trade 

4.7.    Market Impact Analysis In 2020 (Quarter Wise)

5.    Global Biologics Market, By Drug Class

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Drug Class

5.1.2.    BPS Analysis, By Drug Class

5.2.    Market Revenue (US$Mn) and Forecast, By Drug Class

5.2.1.    Monoclonal Antibody

5.2.2.    Vaccine

5.2.3.    Recombinant Insulin

5.2.4.    Human Growth Hormone

5.2.5.    Blood Factor

5.2.6.    Fusion Protein

5.2.7.    Erythropoietin

5.2.8.    Recombinant Enzyme

5.2.9.    Interferon

5.2.10.    Colony-stimulating Factor

5.2.11.    Cell Therapy

5.2.12.    Gene Therapy

5.2.13.    Oligonucleotides

5.3.    Global Biologics Market Attractiveness Index, By Drug Class

6.    Global Biologics Market, By Therapeutic Application

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Therapeutic Application

6.1.2.    BPS Analysis, By Therapeutic Application

6.2.    Market Revenue (US$Mn) and Forecast, By Therapeutic Application

6.2.1.    Oncology 

6.2.2.    Metabolic Disorders

6.2.3.    Autoimmune/Immunologic Diseases

6.2.4.    Ophthalmic Diseases

6.2.5.    Inflammatory Bowel Diseases (IBDs)

6.2.6.    Respiratory Disorder

6.2.7.    Neurological Disorders

6.2.8.    Musculoskeletal Disorders (MSDs)

6.2.9.    Cardiovascular Diseases (CVDs)

6.2.10.    Infectious Diseases

6.2.11.    Others

6.3.     Global Biologics Market Attractiveness Index, By Therapeutic Application

7.    Global Biologics Market, By Distribution Channel

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Distribution Channel

7.1.2.    BPS Analysis, By Distribution Channel

7.2.    Market Revenue (US$Mn) and Forecast, By Distribution Channel

7.2.1.    Hospital Pharmacies

7.2.2.    Retail Pharmacies

7.2.3.    Online Pharmacies

7.3.    Global Biologics Market Attractiveness Index, By Distribution Channel

8.    Global Biologics Market, By Region

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Region

8.1.2.    BPS Analysis, By Region

8.2.    Market Revenue (US$Mn) and Forecast, By Region

8.2.1.    North America

8.2.2.    Latin America

8.2.3.    Europe

8.2.4.    Asia Pacific

8.2.5.    Middle East 

8.2.6.    Africa

8.3.    Global Biologics Market Attractiveness Index, By Region

9.    North America Biologics Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market Revenue (US$Mn) and Forecast, By Country

9.2.1.    U.S. Biologics Market

9.2.2.    Canada Biologics Market

9.3.    North America Biologics Market, By Drug Class

9.3.1.    Grade III A

9.3.2.    Grade III

9.3.3.    Grade III B

9.3.4.    Grade IV

9.4.    North America Biologics Market Revenue (US$Mn) and Forecast, By Therapeutic Application

9.4.1.    Transparent

9.4.2.    Opaque

9.5.    North America Biologics Market Revenue (US$Mn) and Forecast, By Distribution Channel

9.5.1.    Riot Shields

9.5.2.    Helmet Visors

9.5.3.    Vehicular Bulletproofing

9.6.    North America Biologics Market Attractiveness Index

9.6.1.    By Country

9.6.2.    By Drug Class

9.6.3.    By Therapeutic Application

9.6.4.    By Distribution Channel

10.    Latin America Biologics Market Analysis and Forecast, 2020–2028

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    Brazil Biologics Market

10.2.2.    Mexico Biologics Market

10.2.3.    Rest Of Latin America Biologics Market

10.3.    Latin America Biologics Market, By Drug Class

10.3.1.    Grade III A

10.3.2.    Grade III

10.3.3.    Grade III B

10.3.4.    Grade IV

10.4.    Latin America Biologics Market Revenue (US$Mn) and Forecast, By Therapeutic Application

10.4.1.    Transparent

10.4.2.    Opaque

10.5.    Latin America Biologics Market Revenue (US$Mn) and Forecast, By Distribution Channel

10.5.1.    Riot Shields

10.5.2.    Helmet Visors

10.5.3.    Vehicular Bulletproofing

10.6.    Latin America Biologics Market Attractiveness Index

10.6.1.    By Country

10.6.2.    By Drug Class

10.6.3.    By Therapeutic Application

10.6.4.    By Distribution Channel

11.    Europe Biologics Market Analysis and Forecast, 2020–2028

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    U.K. Biologics Market

11.2.2.    Germany Biologics Market

11.2.3.    Italy Biologics Market

11.2.4.    France Biologics Market

11.2.5.    Spain Biologics Market

11.2.6.    Russia Biologics Market

11.2.7.    Rest Of Europe Biologics Market

11.3.    Europe Biologics Market, By Drug Class

11.3.1.    Grade III A

11.3.2.    Grade III

11.3.3.    Grade III B

11.3.4.    Grade IV

11.4.    Europe Biologics Market Revenue (US$Mn) and Forecast, By Therapeutic Application

11.4.1.    Transparent

11.4.2.    Opaque

11.5.    Europe Biologics Market Revenue (US$Mn) and Forecast, By Distribution Channel

11.5.1.    Riot Shields

11.5.2.    Helmet Visors

11.5.3.    Vehicular Bulletproofing

11.6.    Europe Biologics Market Attractiveness Index

11.6.1.    By Country

11.6.2.    By Drug Class

11.6.3.    By Therapeutic Application

11.6.4.    By Distribution Channel

12.    Asia Pacific Biologics Market Analysis and Forecast, 2020–2028

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Country

12.1.2.    BPS Analysis, By Country

12.2.    Market (US$Mn) Forecast, By Country

12.2.1.    China Biologics Market

12.2.2.    India Biologics Market

12.2.3.    Japan Biologics Market

12.2.4.    Australia and New Zealand Biologics Market

12.2.5.    South Korea Biologics Market

12.2.6.    Rest of Asia Pacific Biologics Market

12.3.    Asia Pacific Biologics Market, By Drug Class

12.3.1.    Grade III A

12.3.2.    Grade III

12.3.3.    Grade III B

12.3.4.    Grade IV

12.4.    Asia Pacific Biologics Market Revenue (US$Mn) and Forecast, By Therapeutic Application

12.4.1.    Transparent

12.4.2.    Opaque

12.5.    Asia Pacific Biologics Market Revenue (US$Mn) and Forecast, By Distribution Channel

12.5.1.    Riot Shields

12.5.2.    Helmet Visors

12.5.3.    Vehicular Bulletproofing

12.6.    Asia Pacific Biologics Market Attractiveness Index

12.6.1.    By Country

12.6.2.    By Drug Class

12.6.3.    By Therapeutic Application

12.6.4.    By Distribution Channel

13.    Middle East Biologics Market Analysis and Forecast, 2020–2028

13.1.    Introduction

13.1.1.    Annual Growth Rate Comparison, By Country

13.1.2.    BPS Analysis, By Country

13.2.    Market (US$Mn) Forecast, By Country

13.2.1.    GCC Countries Biologics Market

13.2.2.    Israel Biologics Market

13.2.3.    Rest Of Middle East Biologics Market

13.3.    Middle East Biologics Market, By Drug Class

13.3.1.    Grade III A

13.3.2.    Grade III

13.3.3.    Grade III B

13.3.4.    Grade IV

13.4.    Middle East Biologics Market Revenue (US$Mn) and Forecast, By Therapeutic Application

13.4.1.    Transparent

13.4.2.    Opaque

13.5.    Middle East Biologics Market Revenue (US$Mn) and Forecast, By Distribution Channel

13.5.1.    Riot Shields

13.5.2.    Helmet Visors

13.5.3.    Vehicular Bulletproofing

13.6.    Middle East Biologics Market Attractiveness Index

13.6.1.    By Country

13.6.2.    By Drug Class

13.6.3.    By Therapeutic Application

13.6.4.    By Distribution Channel

14.    Africa Biologics Market Analysis and Forecast, 2020–2028

14.1.    Introduction

14.1.1.    Annual Growth Rate Comparison, By Country

14.1.2.    BPS Analysis, By Country

14.2.    Market (US$Mn) Forecast, By Country

14.2.1.    South Africa Countries Biologics Market

14.2.2.    Egypt Biologics Market

14.2.3.    North Africa Biologics Market

14.2.4.    Rest of Africa Biologics Market

14.3.    Africa Biologics Market, By Drug Class

14.3.1.    Grade III A

14.3.2.    Grade III

14.3.3.    Grade III B

14.3.4.    Grade IV

14.4.    Africa Biologics Market Revenue (US$Mn) and Forecast, By Therapeutic Application

14.4.1.    Transparent

14.4.2.    Opaque

14.5.    Africa Biologics Market Revenue (US$Mn) and Forecast, By Distribution Channel

14.5.1.    Riot Shields

14.5.2.    Helmet Visors

14.5.3.    Vehicular Bulletproofing

14.6.    Africa Biologics Market Attractiveness Index

14.6.1.    By Country

14.6.2.    By Drug Class

14.6.3.    By Therapeutic Application

14.6.4.    By Distribution Channel

15.    Competitive Landscape

15.1.    Company Profiles

15.1.1.    Bristol-Myers Squibb Company (BMS)

15.1.1.1.    Company Overview

15.1.1.2.    Financial Overview

15.1.1.3.    Key Developments

15.1.1.4.    Strategies

15.1.1.5.    Product Analysis

15.1.2.    Merck & Co., Inc.

15.1.3.    Roche AG

15.1.4.    Merck KGaA

15.1.5.    AstraZeneca Plc

15.1.6.    Regeneron Pharmaceuticals, Inc

15.1.7.    Novartis International AG

15.1.8.    Pfizer Inc.

15.1.9.    Amgen, Inc.

15.1.10.    AbbVie, Inc.

15.1.11.    Sanofi S.A.

15.1.12.    Eli Lilly & Company

15.1.13.    Novo Nordisk A/S

15.1.14.    Johnson & Johnson

15.1.15.    GlaxoSmithKline Plc

15.1.16.    Teva Pharmaceutical Industries Ltd.

15.1.17.    Ipsen S.A.

15.1.18.    Allergan Plc.

16.    Acronyms

Select License Type

Frequently Asked Questions

The global biologics market was valued US$ 294.4 Bn at the end of 2020 and expected to reach at a value of US$ 529.3 Bn by 2028 with a significant CAGR of 7.6%.

the rising incidence of chronic diseases such as autoimmune diseases, diabetes, and cancer among the population owing to the lethargic lifestyle, poor diet, and desk-bound jobs is mainly encouraging the demand of biologics in the global market

The research report classifies the global biologics market based on drug class, therapeutic application, distribution channel, and regions.

Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc are the key participating players in the market



This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

OK